Leonard van den Berg

Leonard van den Berg

Professor of Neurology and Chair of TRICALS

Leonard van den Berg is professor of neurology and chairman of TRICALS. He is also director of The Netherlands ALS Center, which aims to improve the diagnosis, treatment/care and scientific research for ALS in the Netherlands. As chairman of the European Network to find the Cure for ALS (ENCALS), as initiator of the worldwide ALS genetics research Project MinE and as coordinator of awarded EU grants (FP7 Euro-MOTOR (systems biology) and JPND SOPHIA (biomarkers), he is strongly committed to international collaborations on ALS research.

He has been the principle investigator of multiple multicenter clinical trials and in 2015 he established the Treatment Research Initiative to Cure ALS to accelerate the search for a cure.

Connect
Connect trials
Recruiting
Phase iii

ATLAS study

Industry trial

Biogen is conducting a clinical trial to evaluate the efficacy and safety and of an investigational drug for adults who do not have any clinical signs or symptoms of ALS but do carry a certain superoxide dismutase 1 (SOD1) gene variant.

Read more
Recruiting
Phase iii

PHOENIX trial

Industry trial

Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.

Read more
Recruiting
Phase iii

ADORE Trial

Industry trial

Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).

Read more
Recruiting
Phase iii

COURAGE-ALS Trial

Industry trial

In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.

Read more
Active
Phase ii

APL2-ALS-206 Trial

Industry trial

In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.

Read more
Active
Phase ii

RT001 in Amyotrophic Lateral Sclerosis

Industry trial

In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.

Read more
Recruiting
Phase iii

TUDCA-ALS

Investigator initiated trial

This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.

Read more